Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-angiogenesis therapy for the treatment of previously treated breast cancer

A technology for breast cancer and metastatic breast cancer, applied in the field of anti-angiogenic therapy for the treatment of previously treated breast cancer, which can solve the problems of detection and treatment difficulties

Inactive Publication Date: 2012-07-11
F HOFFMANN LA ROCHE & CO AG
View PDF51 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cancer (or malignancy) grows and spreads rapidly in an uncontrolled manner, making timely detection and treatment extremely difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-angiogenesis therapy for the treatment of previously treated breast cancer
  • Anti-angiogenesis therapy for the treatment of previously treated breast cancer
  • Anti-angiogenesis therapy for the treatment of previously treated breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0251] Example 1. Bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer

[0252] Metastatic breast cancer (MBC) is an incurable disease and most patients die from their disease within 2 years of diagnosis. See Greenberg, et al., 1996, J. Clin. Oncol. 14:2197-205. Following adjuvant therapy, approximately 60% of patients with advanced disease present with local recurrence and 40% with distant metastasis. Only 10% of patients present with metastatic disease at initial diagnosis. See Ryberg et al., 2001 Ann. Oncol. 12:81-7.

[0253] The treatment strategy for patients with MBC is based on several factors, including clinical, pathological, and histological features, such as human epidermal growth factor-2 (HER2) amplification, hormone receptor status, prior response to hormonal agents, and / or or failure, number and specific site of metastatic disease, and treatment history in both metastatic and adjuvant settings. N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This disclosure concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the disclosure concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer.

Description

[0001] related application [0002] This application claims the priority and rights of U.S. Provisional Application Serial No. 61 / 266,343 filed on December 3, 2009 and U.S. Provisional Application Serial No. 61 / 234,281 filed on August 15, 2009, and their specifications are fully incorporated herein. field of invention [0003] Generally, the present invention relates to the treatment of human diseases and pathological conditions. More specifically, the present invention relates to the use of anti-angiogenic therapy alone or in combination with other anti-cancer therapies in the treatment of previously treated breast cancer. Background of the invention [0004] Cancer remains one of the deadliest threats to human health. Cancer affects nearly 1.3 million new patients each year in the United States and is the second leading cause of death after heart disease, accounting for about 1 in 4 deaths. It is also predicted that cancer may overtake cardiovascular disease as the numbe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P35/00G16H20/10
CPCC07K16/22A61K39/39558A61K45/06G06Q99/00C07K2317/56A61K31/337G06Q30/0269A61P15/00A61P35/00A61P35/04A61P43/00G16H20/10Y02A90/10A61K2300/00G06Q50/22A61K2039/505A61K2121/00
Inventor R.斯瓦米J.汉布尔顿
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com